Octocog alfa  (Synonyms: ADVATE; BAY 81-8973; Kovaltry)

Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A^[1][2][3].

At a single dose of 50 IU/kg, octocog alfa maintains the average FVIII activity level above 40 IU/dL for less than 1 day, above 10 IU/dL for less than 2 days, and causes no significant changes in coagulation biomarker levels before and after infusion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

139076-62-3

[Octocog alfa]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Müller J, et al. Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A. Haemophilia. 2024;30(5):1203-1209.

  [2]. Lissitchkov T, et al. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. Res Pract Thromb Haemost. 2023;7(4):100176. Published 2023 May 13.

  [3]. Klamroth R, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. Haemophilia. 2016;22(5):730-738.